-

Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.

The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides, and conjugated therapeutics. Applications such as aggregate characterization, molecular weight confirmation and size distribution analysis remain essential for evaluating product quality, stability and performance, while drug-to-antibody ratio determination is critical for characterizing antibody-drug conjugates and other conjugated therapeutics as drug modalities continue to increase in complexity.

“Customer reception of the first wave of Altura columns has been overwhelmingly positive, highlighting strong demand for high-performance inert column solutions," said David Edwards, vice president and general manager of Agilent's Chemistries and Supplies Division. "By extending the Altura HPLC columns with Ultra Inert technology to SEC and PLRP-S columns, we are expanding access to inert separation technologies that help scientists achieve more reliable, accurate and reproducible results across critical biopharma analytical workflows."

Aggregate analysis is a critical quality attribute for a wide range of biotherapeutics, including monoclonal antibodies, antibody-drug conjugates, and emerging modalities. Altura SEC columns build on the success of the Agilent AdvanceBio SEC columns while incorporating Ultra Inert technology to enhance peak shape and aggregate recovery. For aggregate analysis of GLP-1 peptides, Altura SEC columns deliver up to double the sensitivity of inert competitor columns, improving detection of low-level impurities.

For liquid chromatography/mass spectrometry (LC/MS) workflows, Altura PLRP-S columns are designed to deliver robust performance under demanding conditions. These capabilities support molecular weight confirmation across protein-based therapeutics and complex biopharmaceutical modalities.

The new columns are engineered to deliver faster conditioning, improved peak shape and enhanced sensitivity for challenging analytes. These performance improvements support a broad range of therapeutic modalities, from peptide therapeutics such as GLP-1 to oligonucleotides and large biomolecules including monoclonal antibodies and mRNA. As analytical demands continue to evolve, laboratories require robust and reproducible solutions to support development and quality workflows.

"In our core lab, we depend on columns that can handle a wide range of applications and complex matrices," said Yanan Yang, Ph.D., director of the MS Center at MBC BioLabs. "Agilent's Altura columns — especially HILIC-Z, Eclipse Plus and PLRP-S — have delivered excellent peak shape, strong reproducibility and reliable performance even after hundreds or even thousands of injections across challenging workflows."

Altura columns are part of Agilent's broader portfolio of inert liquid chromatography solutions, designed to provide a fully optimized sample flow path when used in conjunction with Agilent instrumentation and supplies. This integrated approach helps laboratories improve workflow efficiency while maintaining data quality and consistency. The Altura SEC and Altura PLRP-S columns are available globally.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

MEDIA CONTACT:
Kate Coyle
Agilent Technologies Inc.
+1 302-633-7490
kate.coyle@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

MEDIA CONTACT:
Kate Coyle
Agilent Technologies Inc.
+1 302-633-7490
kate.coyle@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the NovoStation Sample Preparation System, a new automated platform designed to help laboratories simplify and streamline flow cytometry sample preparation. When paired with a NovoCyte flow cytometer and NovoExpress software, NovoStation offers an integration-ready solution that enables a hands-free sample-to-answer workflow, helping scientists spend less time preparing samples and more time...

Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent BioTek Gen5 AI cell identification module, a new image analysis software add-on that incorporates AI-based cell identification and segmentation into BioTek Gen5 imaging analysis. Developed for use with compatible Agilent BioTek automated imaging systems, the module uses AI-based segmentation without requiring conventional threshold setting or parameter tuning. By incorporating the...

Agilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent 4150 TapeStationDx system, Agilent 4200 TapeStationDx system and Agilent TapeStationDx software, extending the company's automated electrophoresis portfolio into regulated clinical laboratory environments. The new CE-IVD-labeled systems and software are designed to support standardized and traceable quality control of DNA and RNA samples used in clinical next-generation sequencing...
Back to Newsroom